Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Butt

Showing results (281-290 of 309) with videos related to

Pageof 31
Sort By:
JACC. Heart Failure|April 4, 2024
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Pardeep S Jhund, Kieran F Docherty, et al.
Nature Communications|February 26, 2026
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trialJian L Campian, Son B Le, Ashley Ghiaseddin, et al.
Science Translational Medicine|June 14, 2023
Gut microbiome composition may be an indicator of preclinical Alzheimer's diseaseAura L Ferreiro, JooHee Choi, Jian Ryou, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomasOmar H Butt, Kartik Singhal, Jingqin Luo, et al.
JAMA Cardiology|February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVERJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation. Heart Failure|October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVERToru Kondo, Jawad H Butt, James P Curtain, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 31

Showing results (281-290 of 309) with videos related to

Sort By:
Pageof 31
JACC. Heart Failure|April 4, 2024
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVERJawad H Butt, Pardeep S Jhund, Kieran F Docherty, et al.
Nature Communications|February 26, 2026
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trialJian L Campian, Son B Le, Ashley Ghiaseddin, et al.
Science Translational Medicine|June 14, 2023
Gut microbiome composition may be an indicator of preclinical Alzheimer's diseaseAura L Ferreiro, JooHee Choi, Jian Ryou, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomasOmar H Butt, Kartik Singhal, Jingqin Luo, et al.
JAMA Cardiology|February 22, 2023
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVERJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation. Heart Failure|October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVERToru Kondo, Jawad H Butt, James P Curtain, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
Pageof 31